Background: Therapeutic utilities of doxorubicin (DOX), an anticancer anthracycline antibiotic, are limited by its serious dosedependent toxicity to non-target tissues such as testis. The aim of the present study was to elucidate the potential of simvastatin (SIM), a lipid lowering agent with antioxidant and anti-inflammatory activities, to attenuate DOX-induced spermatotoxicity in male mice. M...
